BioSpace News Archive

Ventyx Biosciences, Inc. announced that Company executives will participate in the following upcoming investor conferences.

RAPT Therapeutics, Inc. announced that members of the RAPT management team will participate in the following investor conferences in September:

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor (ILBM), which provides accurate and continuous measurement of essential blood parameters to perfusionists throughout cardiopulmonary bypass (CPB) procedures.

Longboard Pharmaceuticals, Inc. announced that it will present new and encore data at the 35th International Epilepsy Congress and the American College of Clinical Pharmacology Annual Meeting.

Disc Medicine, Inc. announced that company management will participate in fireside chats at four upcoming investor conferences.

ORIC Pharmaceuticals, Inc. announced that management will participate in the following investor conferences in the first half of September.

Tarsus Pharmaceuticals, Inc. announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Strategy Officer, will participate in the following conferences, both located in New York City, NY.

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2023 and provided a summary of recent corporate highlights.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the successful initiation of the second IgA nephropathy (IgAN) dose cohort in RUBY-3, a phase 1b/2a study in autoimmune glomerulonephritis.

ADC Therapeutics SA (NYSE: ADCT) today announced that two ZYNLONTA® (loncastuximab tesirine-lpyl) abstracts have been accepted for presentation at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023), which will be held in Houston, Texas from September 6-9, 2023.